A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignancies

Oncologist

Volumn 15, Issue 9, 2010, Pages 954-960

  Burris III, Howard A ^a,b   Infante, Jeffrey R ^a,b   Jewell, Roxanne C ^c   Spigel, David R ^a,b   Greco, F Anthony ^a,b   Thompson, Dana S ^b   Jones, Suzanne F ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Advanced solid tumors; Hematologic toxicity; Pemetrexed; Pharmacokinetics; Topotecan

Indexed keywords

PEMETREXED; TOPOTECAN;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; TOPOTECAN;

EID: 77957770437     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0006     Document Type: Article

References (23)

1. Lynch TJ Jr, Kalish L, Strauss G et al. Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 1994;12:347-352.
2. Perez-Soler R, Fossella FV, Glisson BS et al. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 1996;14:503-513.
3. Weitz JJ, Marschke RF Jr, Sloan JA et al.Arandomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung Cancer 2000;28:157-162.
4. Mainwaring PN, Nicolson MC, Hickish T et al. Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: No evidence of increased efficacy. Br J Cancer 1997;76:1636-1639.
5. Kindler HL, Kris MG, Smith IE et al. Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer. Am J Clin Oncol 1998;21: 438-441.
6. White SC, Cheeseman S, Thatcher N et al. Phase II study of oral topotecan in advanced non-small cell lung cancer. Clin Cancer Res 2000;6:868-873.
7. Ramlau R, Gervais R, Krzakowski M et al. Oral topotecan demonstrates clinical activity in relapsed non-small cell lung cancer. Results from an open-label, phase III study (387) comparing oral topotecan to intravenous docetaxel [abstract]. J Clin Oncol 2005;23:7017.
8. Eckardt JR. Feasibility of oral topotecan plus intravenous paclitaxel in advanced non-small-cell lung cancer. Oncology 2001;61(suppl 1):30-34.
9. Stupp R, Bodmer A, Duvoisin B et al. Is cisplatin required for the treatment of non-small-cell lung cancer? Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine. Oncology 2001;61(suppl 1): 35-41.
10. Pujol JL, von Pawel J, Tumolo S et al. Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer. Oncology 2001;61(suppl 1):47-54.
11. Raymond E, Burris HA, Rowinsky EK et al. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma. Ann Oncol 1997;8:1003-1008.
12. Guarino MJ, Schneider CJ, Grubbs SS et al. A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer. The Oncologist 2002;7:509-515.
13. Joppert MG, Garfield DH, GregurichMAet al.Aphase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2003;39:215-219.
14. Dowlati A, Levitan N, Gordon NH et al. Phase II and pharmacokinetic/ pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2001;47:141-148.
15. Dobbs T, Eckardt J, FanucchiMet al. Oral topotecan (OT) and intravenous paclitaxel (P) in patients with advanced non-small cell lung cancer (NSCLC): A phase I/II study [abstract]. J Clin Oncol 2000;19:2049.
16. Rinaldi DA, Lormand NA, Brierre JE et al. A phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma. Cancer 2002;95:1274-1278.
17. Rinaldi D, Lormand N, Brierre J et al. A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3). Cancer Invest 2001;19:467-474.
18. Larocca RV, Glisson S, Hargis J et al. Biweekly topotecan and gemcitabine in advanced small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC): A phase I study [abstract]. J Clin Oncol 2003;22:2734.
19. Dabrow MB, Francesco MR, Gilman PB et al. Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic nonsmall cell lung cancer. Cancer Invest 2003;21:517-525.
20. Rusthoven JJ, Eisenhauer E, Butts C et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced nonsmall- cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999;17:1194.
21. Clarke SJ, Abratt R, Goedhals L et al. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 2002;13:737-741.
22. Smit EF, Mattson K, von Pawel J et al. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: A phase II study. Ann Oncol 2003;14:455-460.
23. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.